Expression of Epstein-Barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV

J J Oudejans, D F Dukers, N M Jiwa, A J C van den Brule, F A Grässer, P C de Bruin, A Horstman, W Vos, J van Gorp, J M Middeldorp, C J L M Meijer

Abstract

Aims—To determine levels of expression of Epstein-Barr virus (EBV) nuclear antigen 1 (EBNA1) in benign and malignant tissues harbouring EBV in relation to EBNA1 promoter usage.

Methods—Expression of EBNA1 was investigated by means of immunohistochemistry using a mixture of two EBNA1 specific monoclonal antibodies, 1H4-1 and 2B4-1. The presence of EBV was detected by EBER1/2 RNA in situ hybridisation. Detection of promoter specific EBNA1 transcripts was by RT-PCR analysis.

Results—EBNA1 positive cells were detected in all 20 EBV associated B cell lymphomas, 18 of which had arisen in immunocompromised patients; in eight of nine EBV associated T cell lymphomas; in 11 of 27 EBV positive cases of Hodgkin’s disease; and in reactive lymphoid tissue harbouring EBV, including four cases of infectious mononucleosis. A diffuse EBNA1 staining pattern was observed in most of the EBV associated B cell lymphomas and was comparable with the EBER1/2 staining pattern. In the T cell lymphomas the number of EBNA1 positive cells was usually considerably less than the number of EBER1/2 positive ones. RT-PCR analysis revealed that in tumours with restricted EBNA1 expression—that is, T cell lymphomas and Hodgkin’s disease lesions, EBNA1 transcripts were usually generated only by the F/Q promoter, whereas in B cell lymphomas EBNA1 transcripts were usually generated by both the C/W and F/Q promoters.

Conclusions—EBNA1 is expressed in all types of tissue harbouring EBV, but the level of expression varies greatly. This may be the result of differential promoter usage.

(J Clin Pathol 1996;49:897–902)

Keywords: Epstein-Barr virus, EBNA1, lymphoma.

Epstein-Barr virus (EBV) is the aetiological agent in infectious mononucleosis and has been implicated in the pathogenesis of a growing number of malignancies. Classically, EBV is associated with African Burkitt’s lymphoma, with nasopharyngeal carcinomas and B cell lymphomas arising in immunosuppressed patients. More recently, using a highly sensitive RNA in situ hybridisation assay, EBV has been detected in the neoplastic cells of a substantial number of cases of Hodgkin’s disease and in certain types of T cell lymphomas, especially those localised to the nose, lungs and gastrointestinal tract. B cell lymphomas arising in patients without overt immune deficiency are sporadically associated with EBV.

In studying EBV latent gene expression in lymphomas, EBV nuclear antigen 2 (EBNA2) and latent membrane protein 1 (LMP-1) have been of particular interest, because these are essential for the transforming effect of EBV. An aetiological role for EBV in many EBV associated malignancies may be mediated by LMP-1. By contrast, the pathogenic role of EBNA2 in vivo seems to be restricted, as expression of EBNA2 has been detected only in B cell lymphomas arising in immunocompromised patients.

Recently, several reports have indicated that EBNA1 is not only involved in viral plasmid DNA replication and maintenance of viral episomes in the cell, but may also play a more active role in the pathogenesis of lymphomas. Srinivas and Sixty showed that expression of EBNA1 induces expression of V(D)J recombine activating genes RAG1/2, whose aberrant activity has been implicated in chromosomal translocations in haematological neoplasms.

Regulation of EBNA1 transcription is complex. In EBV transformed lymphoblastoid cell lines and in post-transplant B cell lymphomas, EBNA1 and other EBV mRNAs are derived from highly spliced transcripts that are generated by one of two promoters located on the Bam HI fragments C and W and referred to as the C/W promoter. Selective expression of EBNA1 without expression of the other EBNAs in other EBV associated malignancies (including Burkitt’s lymphoma, Hodgkin’s disease, T cell lymphomas, and nasopharyngeal carcinomas) results from activation of a separate EBNA1 promoter, probably located on the Bam HI Q fragment and referred to as the Q promoter. In lytic EBV infection EBNA1 transcripts are generated by the F promoter located just upstream from the Q promoter.
It is possible that the putative oncogenic effect of EBNA1 is related to its level of expression. Recently, EBNA1 specific antibodies became available, enabling the detection of EBNA1 on conventional paraffin wax embedded tissue sections. Using these antibodies, we investigated whether there are differences in the level of expression of EBNA1 in benign and malignant lesions harbouring EBV. Reverse transcription polymerase chain reaction (RT-PCR) analysis was also carried out to investigate whether such differences could be explained by differential usage of the EBNA1 promoters.

Methods
Paraffin wax sections from 18 lymphomas arising in immunocompromised patients, 12 post-transplant lymphomas and six AIDS related B cell lymphomas, and two B cell lymphomas, nine T cell lymphomas and 27 cases of Hodgkin's disease, all arising in patients without overt immune deficiency, and four cases of infectious mononucleosis were studied. In all cases the presence of EBV was demonstrated by EBER1/2 RNA in situ hybridisation, as described previously. Lymphomas with more than 70% EBER1/2 positive neoplastic cells were considered to be EBV associated. One hyperplastic tonsil and one reactive lymph node harbouring sporadic EBER1/2 positive small lymphocytes were also analysed.

Non-Hodgkin's lymphomas were classified according to the updated Kiel classification and the REAL classification, with the exception of some of the post-transplant lymphomas and AIDS related lymphomas, which are difficult to classify according to the Kiel classification because of their notable polymorphism. Cases of Hodgkin's disease were classified according to the Rye classification. If snap frozen material was available, RNA was isolated for RT-PCR.

EBV positive cell lines JY (EBV transformed lymphoblastoid cell line) and RAJI (a Burkitt's lymphoma derived cell line) served as positive controls for both immunohistochemistry and RT-PCR. Negative controls consisted of two EBV negative cell lines (RAMOS, BJAB) and of several cases of EBV negative Hodgkin's disease and non-Hodgkin's lymphoma.

IMMUNOHISTOCHEMISTRY
The specificities of rat monoclonal antibodies 1H4-1 and 2B4-1 directed against EBNA1 have been described elsewhere. Immunohistochemistry was performed on paraffin wax sections, fixed either in buffered formaldehyde or sublimate formaldehyde. Briefly, tissue sections were deparaffinised in xylene and incubated with hydrogen peroxidase to block endogenous peroxidase. After antigen retrieval in 0.1 mol/l citrate buffer, pH 6.0, for 10 minutes in a pressure cooker, tissue sections were washed, pre-incubated with normal serum and incubated with a mixture of 1H4-1 (rat IgG2a) and 2B4-1 (rat IgG1) for one hour at a dilution of 1 in 200. Subsequently, sections were incubated with biotinylated goat anti-rat followed by incubation with an ABC horse radish peroxidase (HRP) complex (Dako, Glostrup, Denmark). Amplification of signal intensity was obtained by deposition of biotinylated tyramine (BT) on the bound ABC-HRP complex through the enzymatic reaction between tyramine and HRP. This was followed by a second incubation period with ABC-HRP. Diaminobenzidine (DAB) was used as the chromogen. Inclusion of this amplification step enhanced the staining intensities and revealed greater numbers of EBNA1 positive cells compared with the routine ABC method lacking this step.

In T and B cell lymphomas the number of EBER1/2 and EBNA1 positive cells was estimated visually, as described by Weiss et al, with slight modifications. Using a ×12.5 ocular and a ×25 objective for screening the tissue slides, lymphomas were divided into diffuse (over 100 cells per medium power field (mpf)), clustered (between 25 and 100 cells per mpf), scattered (less than 25 cells per mpf) or single cell (less than one cell per mpf) positive cases. Negative controls included isotype matched rat monoclonal antibodies.

RT-PCR
RT-PCR analysis was performed using intron flanking primers. Two primer combinations were used to detect EBNA1 specific transcripts. One set was used to detect Y3/U/K spliced transcripts, probably generated by the C/W promoter, and the other to detect Q/U/K spliced transcripts generated by the F/Q promoter. Cases were excluded if the mRNA seemed to be of poor quality, as determined by RT-PCR using primers specific for U1A and for rightward reading EBV transcripts from the Bam HI A region (BARF0), which is present in all tissue harbouring EBV. The primer sequences and oligo probes used for analysis of EBNA1 and BARF0 were reported previously. The conditions used for RNA isolation, RT-PCR analysis and Southern blot hybridisation have been described elsewhere. In all experiments positive and negative controls were included to test the specificity and sensitivity of the RT-PCR conditions.

Results
EBNA1 expression in B cell lymphomas arising in immunocompromised patients
Table 1 summarises the results. All 18 cases were diffuse large B cell proliferations with a diffuse EBER1/2 staining pattern. In all cases EBNA1 positive cells displayed the nuclear, fine granular staining pattern characteristic of EBNA1 reactivity.
A diffuse EBNA1 staining pattern was observed in 14 cases, with strong EBNA1 positivity in most of the neoplastic cells (fig 1A). In three cases clustered EBNA1 positive cells were observed while scattered EBNA1 positive cells were present in another case. The EBER1/2 staining pattern was diffuse in all cases.
Expression of EBNA1 in benign and malignant tissues harbouring EBV

Table 1 Patterns of expression of EBER1/2 and EBNA1 in EBV associated B cell lymphoproliferative disorders

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number of cases</th>
<th>EBER1/2</th>
<th>EBNA1 protein</th>
<th>EBNA1 mRNA</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Diffuse</td>
<td>Clustered</td>
<td>Scattered</td>
</tr>
<tr>
<td>Immunocompromised patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Post-transplant lymphomas</td>
<td>12</td>
<td>12</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>AIDS related lymphomas</td>
<td>6</td>
<td>6</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Patients without overt immune deficiency</td>
<td>2</td>
<td>2</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>
| B cell lymphomas                 |                 |         |               |            |         |       |       | *One case harboured Y3/U/K spliced EBNA1 transcripts and the other case Q/U/K spliced EBNA1 specific transcripts.

Figure 1 (A) EBNA1 is expressed strongly in neoplastic cell nuclei of patients with B cell lymphoma. (B) EBNA1 expression in a nodal T cell lymphoma. Positive neoplastic cells are indicated by arrowheads. (C) EBER1/2 expression in the same nodal T cell lymphoma. In this case the EBNA1 positive cells are clearly outnumbered by the EBER1/2 positive cells. (D) EBV associated Hodgkin's disease. EBNA1 is expressed in most H-RS cells. (E) Reactive lymph node. Sporadic EBNA1 positive lymphocytes are present in the paracortex (arrows).

RT-PCR analysis revealed the presence of Y3/U/K spliced EBNA1 transcripts, generated by the C/W promoter, in all five cases tested. Additional Q/U/K spliced transcripts, generated by the F/Q promoter, were found in four cases.

EBNA1 expression in B cell lymphomas in patients without overt immune deficiency. Both cases were classified as diffuse large B cell lymphoma or diffuse polymorphous centroblastic lymphoma. A diffuse EBNA1 staining pattern was observed in both cases. RT-PCR...
Table 2  Patterns of expression of EBER1/2 and EBNA1 in EBV associated T cell lymphomas

<table>
<thead>
<tr>
<th>Classification</th>
<th>EBER1/2</th>
<th>EBNA1 protein</th>
<th>EBNA1 mRNA Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients without overt immune deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>T cell lymphoma*</td>
<td>Diffuse</td>
<td>Diffuse</td>
<td>ND/ND Lymph node</td>
</tr>
<tr>
<td>T cell lymphoma</td>
<td>Diffuse</td>
<td>Clustered</td>
<td>ND/ND Lymph node</td>
</tr>
<tr>
<td>LCAL</td>
<td>Diffuse</td>
<td>Diffuse</td>
<td>ND/ND Lymph node</td>
</tr>
<tr>
<td>Diffuse</td>
<td>Diffuse</td>
<td>Clustered</td>
<td>ND/ND Lymph node</td>
</tr>
<tr>
<td>LCAL</td>
<td>Diffuse</td>
<td>Clustered</td>
<td>ND/ND Lymph node</td>
</tr>
<tr>
<td>LCAL</td>
<td>Diffuse</td>
<td>Diffuse</td>
<td>ND/ND Lymph node</td>
</tr>
</tbody>
</table>

*Pleomorphic medium and large cell lymphoma (REAL classification: peripheral T cell lymphoma, unspecified). LCAL = large cell anaplastic lymphoma; ND = not determined.

Table 3  EBNA1 expression in EBV associated Hodgkin’s disease and benign tissues harbouring EBV

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Number of cases</th>
<th>EBNA1 protein</th>
<th>EBNA1 mRNA Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patients without overt immune deficiency</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hodgkin’s disease</td>
<td>27</td>
<td>11</td>
<td>4/4 ND</td>
</tr>
<tr>
<td>Infectious mononucleosis</td>
<td>4</td>
<td>4</td>
<td>ND/ND</td>
</tr>
<tr>
<td>Reactive lymphoid tissue</td>
<td>2</td>
<td>2</td>
<td>0/1/1</td>
</tr>
</tbody>
</table>

*One case harboured both EBNA1 transcripts.††Two of four EBNA1 mRNA positive cases were EBNA1 negative by immunohistochemistry. ND = not determined.

Analysis revealed that in one case EBNA1 specific transcripts were initiated by the F/Q promoter and in the other by the C/W promoter.

Again, the EBER1/2 staining pattern was diffuse in all cases.

EBNA1 expression in T cell lymphomas

Table 2 summarises the results. EBNA1 positive cells were detected in eight of nine EBV associated T cell lymphomas. Again, EBNA1 nuclear staining was seen, but the staining intensity was weaker than that observed in EBNA1 positive cells in the B cell lymphomas. Of the EBV associated T cell lymphomas, three were of nasal origin, all classified as pleomorphic medium and large cell lymphoma and all three had a diffuse EBER1/2 staining pattern. In contrast to the B cell lymphomas, diffuse EBNA1 and EBER1/2 staining patterns were observed in one case only. Clustered EBNA1 positive cells were detected in another case. No EBNA1 positive cells were found in the remaining case.

Of the six nodal T cell lymphomas, four were classified as pleomorphic medium and large cell lymphoma, one case was classified as large cell anaplastic lymphoma (LCAL) and one case was unspecific. A diffuse EBER1/2 staining pattern was observed in two cases, including the LCAL, and a clustered pattern was seen in the remaining four. EBNA1 positive cells were found in all six cases. However, EBER1/2 positive cells usually outnumbered the EBNA1 positive ones (figs 1B and 1C). In one T cell lymphoma and in the single LCAL with a clustered EBER1/2 positive staining pattern, the number of EBNA1 positive cells was comparable with the number of EBER1/2 positive ones.

RT-PCR analysis revealed that in three of five T cell lymphomas tested, EBNA1 transcripts were generated by the F/Q promoter. In the LCAL, however, EBNA1 transcripts were generated by the C/W promoter.

Expression of EBNA1 in patients with Hodgkin’s disease

The data are summarised in table 3. In 11 of 27 EBV associated cases of Hodgkin’s disease, EBNA1 positive staining was observed in the nuclei of the Hodgkin and Reed-Sternberg cells (H-RS cells). In four of these cases, most of the H-RS cells were EBNA1 positive (fig 1D). In the other seven cases EBNA1 positive signals were relatively weak and were only detected in a minority of the H-RS cells. In some cases harbouring EBER1/2 positive small and medium sized cells, these cells were also EBNA1 positive. In one of the four EBNA1 positive cases tested, EBNA1 specific transcripts were generated by the F/Q promoter. In another case, transcripts were generated by both promoters. In two EBER1/2 positive, immunohistochemically EBNA1 negative cases, EBNA1 transcripts were derived from the F/Q promoter.

Expression of EBNA1 in benign tissues harbouring EBV

In infectious mononucleosis the EBNA1 and EBER 1/2 staining patterns were very similar. EBNA1 positive lymphocytes were observed in both specimens of reactive lymphoid tissue harbouring scattered EBER1/2 positive lymphocytes (fig 1E). In the hyperplastic tonsil, EBNA1 transcripts were generated by the F/Q promoter (table 3).

Discussion

Expression of EBNA1 was observed in all EBV associated B cell lymphomas, in eight of nine EBV associated T cell lymphomas, in all cases of infectious mononucleosis, and in some of the EBV associated cases of Hodgkin’s disease. Moreover, in line with previous findings in peripheral blood lymphocytes of healthy EBV seropositive subjects, EBNA1 was expressed at the protein level in latently infected lymphocytes in reactive lymphoid tissues. EBNA1 was most strongly expressed in the EBV associated B cell lymphomas. In most cases a diffuse staining pattern was found, which was comparable with the EBER1/2 staining pattern. Contrasting results were found in EBV associated T cell lymphomas and particularly EBV associated cases of Hodgkin’s disease. One T cell lymphoma did not express EBNA1 and in another six the number of EBNA1 positive cells was considerably smaller than the number of EBER1/2 positive cells. In agreement with previous findings, EBNA1 expression could only be detected in some EBV associated cases of Hodgkin’s disease and generally only in a minority of H-RS cells. LMP-1, however, is usually expressed strongly in almost all H-RS cells in all EBV positive cases. Our findings, in contrast with those of Khan and Naase, suggest that EBNA1 is expressed in at least some cases of EBV associated Hodgkin’s disease.
Expression of EBNA1 in benign and malignant tissues harbouring EBV

As EBNA1 is essential for the maintenance of viral episomes in the cell, the restricted expression of EBNA1 is some cases is probably because EBNA1 was present in concentrations below the detection limit of the antibodies used. This hypothesis is supported by the observation that in several of the cases of B and T cell lymphomas studied here considerably fewer EBNA1 positive cells were identified when the BT signal amplification step was omitted. In addition, we could detect EBNA1 specific transcripts by RT-PCR analysis in two cases of Hodgkin’s disease and in one T cell lymphoma which were both EBNA1 negative by immunohistochemistry. It is also possible that the epitopes recognised by the 1H4-1 and 2B4-1 antibodies were blocked, perhaps by other DNA binding proteins.

When EBNA1 staining results were compared with EBNA1 promoter usage, it seemed that in cases with strong EBNA1 positive staining in the majority of EBER1/2 positive cells (most B cell lymphomas), transcripts were derived from both promoters. In cases with weak EBNA1 positive staining in a minority of EBER1/2 positive cells (most Hodgkin’s disease and T cell lymphomas), transcripts were generally derived from the F/Q promoter, which is in agreement with previous reports. 

The primers used in this study cannot discriminate between EBNA1 transcripts derived from the F and Q promoters. Recently, however, Schaefer et al. showed that the F promoter is activated only during the lytic cycle. Therefore, the Q/U/K spliced EBNA1 transcripts found in cases of Hodgkin’s disease and T cell lymphoma are probably generated by the Q promoter, whereas the Q/U/K spliced transcripts present in four of the five post-transplant lymphomas are probably generated by the F promoter or a mixture of F and Q promoters, as in all of these cases expression of the lytic EBV encoded ZEBRA protein was detected in a minority of cells. 

These data suggest that Q promoter usage results in lower levels of EBNA1 expression than C/W or F promoter usage. Although a (semi-)quantitative RT-PCR assay was not performed, this hypothesis was supported by the differences in signal intensity. Strong amplification signals were observed for both C/W and F promoter derived EBNA1 transcripts in the B cell lymphomas, whereas faint bands were found for the Q promoter derived EBNA1 transcripts in the diffuse EBER1/2 positive T cell lymphomas (fig 2).

These different levels of EBNA1 expression may have implications for the pathogenic role of EBV in the different types of EBV associated lymphomas. It has been shown previously that activation of cellular oncoproteins, such as c-myc, is associated with progression of post-transplant lymphomas and AIDS related lymphomas. In EBV associated cases, the possibility of a translocation occurring may be increased considerably as a result of EBNA1 induced expression of RAG1/2. The relatively strong EBNA1 expression observed in the B cell lymphomas in present study supports the notion that in these lymphomas the occurrence of translocations can be facilitated by EBNA1 induced expression of RAG1/2. In addition, such a mechanism might explain why patients with EBV positive AIDs related lymphoma have a worse prognosis than patients with the EBV negative variant.

In conclusion, consistent with its essential role in maintenance of viral episomes in the host cell, EBNA1 is expressed at the protein level in all types of tissue harbouring EBV, but the level of expression varies greatly. Moreover, our data suggest that these differences are the result of differential EBNA1 promoter usage.

This work was supported by a grant from the Dutch Cancer Society (VU 94-749).

10 Hamilton-Dutoit SJ, Pallesen G. Detection of Epstein-Barr virus small RNAs in routine paraffin sections using


Expression of epstein-barr virus encoded nuclear antigen 1 in benign and malignant tissues harbouring EBV.

J J Oudejans, D F Dukers, N M Jiwa, A J van den Brule, F A Grässer, P C de Bruin, A Horstman, W Vos, J van Gorp, J M Middeldorp and C J Meijer

doi: 10.1136/jcp.49.11.897

Updated information and services can be found at: http://jcp.bmj.com/content/49/11/897

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to: http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to: http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to: http://group.bmj.com/subscribe/